1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Competitor Analysis: VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

The present Competitive Intelligence Report about VEGF Antibodies – Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Recently, VEGF-Trap Eye originating from Regeneron Pharmaceuticals has been approved for cancer and ophthalmic indications. Combined sales of all four VEGF targeting products were US$ 13,192 mln in 2013, of which 53.4% were from oncology sales.


The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation 'biobetter or biosuperior ' molecules as well as of biosimilar copies of the originator products.


The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:


- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.



Table Of Contents

Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors
Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors

Table of Contents


1. Bevacizumab Biosimilars and Biosuperiors

Marketed VEGF Antibodies

-           Avastin Sales and Pipeline

-           Zaltrap Sales and Pipeline

'Next Generation Avastinandrdquo; Pipeline

-           Anti-VEGF Antibody Pipeline

-           Anti-VEGF-Receptor Antibody Pipeline

-           Bispecific Anti-VEGF Antibody Pipeline

Avastin Biosimilar Pipeline


2. Ranibizumab Biosimilars and Biosuperiors

Marketed VEGF Antibody

-           Lucentis Sales and Pipeline

-           Eylea Sales and Pipeline

'Next Generation Lucentisandrdquo; Pipeline

Lucentis Biosimilar Pipeline


3.  Corporate VEGF Antibody Biosimilar and Biobetter Pipelines



View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • January 2017
  • by Transparency Market Research

Global Monoclonal Antibody Therapeutics Market: Overview Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s ...

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

Immunotherapy Drugs Market by Type of Drugs, Therapy Area, End-User, Region - Global Forecast to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, ...

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments

  • $ 4995
  • Industry report
  • December 2016
  • by GBI Research

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments ...


Download Unlimited Documents from Trusted Public Sources

Insulin Market and Diabetes Statistics in the US

  • February 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Hormone Market in the US

  • February 2017
    9 pages
  • Hormone  

    Cytokine  

  • United States  

View report >

Therapy Market and Monoclonal Antibody Market in Japan

  • February 2017
    6 pages
  • Therapy  

    Monoclonal Anti...  

  • Japan  

View report >

Related Market Segments :

Monoclonal Antibody
Targeted Therapy

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.